

GCA, Rheumatoid Arthritis & Drug Usage

Reference Number: RDF2247-24

Date of Response: 29/01/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Dear Royal Devon University Healthcare NHS Foundation Trust,

- In the past 3 months, how many patients with a primary diagnosis of giant cell arteritis (ICD10 codes M31.5 or M31.6) were:*

Date Range 01/10/23 to 31/12/23		
<i>a)</i>	<i>Admitted as an inpatient</i>	9
<i>b)</i>	<i>Treated in A&E</i>	9

- How many patients were treated by the rheumatology department in the past 3 months with the following:*

Date Range 01/10/23 to 31/12/23		
<i>a)</i>	<i>Tocilizumab – for any disease</i>	75
<i>b)</i>	<i>Tocilizumab for rheumatoid arthritis (RA) only</i>	48
<i>c)</i>	<i>Tocilizumab for giant cell arteritis (GCA) only</i>	17

- How many patients were treated by the ophthalmology department (for any disease) in the past 3 months with Tocilizumab?*

Answer: Nil.

- How many patients were treated in A&E in the past 3 months (for any disease) with Tocilizumab?*

Answer: Nil.